Skip to main content
. 2023 Sep 12;18(1):20230756. doi: 10.1515/med-2023-0756

Figure 2.

Figure 2

CDDP-resistant liver cancer cells show glutamine addictive phenotypes. (a) HepG2 parental cells and CDDP-resistant cells were treated with CDDP at the indicated concentrations for 48 h. Cell response to CDDP was determined by cell viability assay and (b) clonogenic assay. (c) Expressions of PTBP1 in HepG2 parental cells and CDDP-resistant cells were examined by Western blot. (d) Glutamine uptake and (e) GLS activity were examined in HepG2 parental and CDDP-resistant cells. (f) HepG2 parental cells and CDDP-resistant cells were cultured with normal or low glutamine condition, cells were treated with CDDP at the indicated concentrations. The cell survival rates were examined by clonogenic assay, (g) cell viability assay, and (h) Annexin V apoptosis assay. *p < 0.05; **p < 0.01; ***p < 0.001.